MOLECULAR AND EXPERIMENTAL PATHOLOGY CORE

分子和实验病理学核心

• 批准号: 7002113
• 负责人: JERROLD A TURNER
• 金额: $ 18.66万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7002113
• 关键词: animal tissue; biomedical facility; disease /disorder model; flow cytometry; gastrointestinal disorder; gastrointestinal system; histopathology; human tissue; immunocytochemistry; inflammatory bowel diseases; intestinal mucosa; laboratory mouse; laser capture microdissection; microarray technology; molecular pathology; mucosal immunity; tissue /cell culture; tissue resource /registry; training

The Molecular Experimental Pathology Core of The University of Chicago DDRCC provides services vital to the study of intestinal disease, particularly immune-mediated, infectious, neoplastic and inflammatory bowel diseases, in human and animal tissues. In simplest terms, the core components can be broken into four major area:;: (1) human and animal (primarily mouse) tissue banking, (2) anatomic pathology review and consultation and tissue analysis (including immunohistochemistry, laser capture microdissection, tissue arrays), and (3) guidance in the use and design of animal nodels of intestinal disease and (4) flow cytometry. The Molecular Experimental Pathology Core was created through ,i reorganization of the Molecular Pathology Core in 2003 in an effort to better meet the needs of the DDRCC. The previous core provided training and direct services in specialized molecular techniques, genetic engineering of both iomatic and embryonic stem (ES) cell lines, and limited access to human tissues and genetic analysis of these tissues. However, due to restructuring of university core services during the previous funding interval, rbr example an excellent University of Chicago Transgenic/Knockout Mouse Core had been established, and advances in science, many of the specialized molecular techniques provided had become routine approaches easily accomplished in an individual investigator's lab or through other University of Chicago Cores, e.g. the DNA Sequencing Con;. A survey of DDRCC membership to determine the services that would best support and extend their work resulted ir a new focus on access to human and animal tissues, access to advanced tools, training in their use, expertise in data inrerpretation, and assistance in the use, rather than development, of mice. Where possible, the Molecular Experimental Pathology Core has partnered with existing resources to generate significant cost-savings to both the core and the DDRCC membership. The Administrative Director of the Molecular Experimental Pathology Core, Dr. Jerrold Turnet M.D., Ph.D., oversees the operations of all components and is directly involved in all human tissue-related operations, provides anatomic pathology review and consultation services, and supervises human and animal tissue immunostaining and tissue array production. The Co-Director of the Molecular Experimental Pathology Core, Dr. Yang-Xin Fu, M.D., Ph.D., directs, the mouse tissue bank, advises on mouse tissue use, provides direct assistance with use and development of animal models, particularly of IBD-related disease, and oversees the operation of flow cytometry services.

芝加哥大学 DDRCC 分子实验病理学核心提供对研究至关重要的服务 人类肠道疾病，特别是免疫介导的、传染性的、肿瘤性的和炎症性的肠道疾病 和动物组织。简单来说，核心部分可以分为四大领域：；：（1）人类和动物 （主要是小鼠）组织库，（2）解剖病理学审查和咨询以及组织分析（包括 免疫组织化学、激光捕获显微切割、组织阵列），以及（3）动物使用和设计的指导 肠道疾病的节点和（4）流式细胞术。分子实验病理学核心是通过 ,i 创建的 2003年重组分子病理学核心，以更好地满足DDRCC的需求。这 以前的核心提供专业分子技术、基因工程方面的培训和直接服务 iomatic 和胚胎干 (ES) 细胞系，并且对人体组织和这些组织的遗传分析的访问有限。 然而，由于上一个资助期间大学核心服务的重组，rbr 的例子是一个很好的例子。 芝加哥大学转基因/基因敲除小鼠核心已经建立，随着科学的进步，许多 提供的专门分子技术已成为个人轻松完成的常规方法 研究人员的实验室或通过其他芝加哥大学核心，例如DNA 测序大会； DDRCC 调查 成员们确定最能支持和扩展其工作的服务导致他们重新关注访问 人类和动物组织、先进工具的获取、使用培训、数据解释方面的专业知识，以及 协助小鼠的使用，而不是发育。在可能的情况下，分子实验病理学核心 与现有资源合作，为核心成员和 DDRCC 成员节省大量成本。 分子实验病理学核心行政主任 Jerrold Turnet 博士负责监督 所有组件的操作，并直接参与所有与人体组织相关的操作，提供解剖学 病理学审查和咨询服务，并监督人体和动物组织免疫染色和组织阵列 生产。分子实验病理学核心联席主任付阳新博士 (M.D., Ph.D.) 指导， 小鼠组织库，为小鼠组织使用提供建议，为动物模型的使用和开发提供直接帮助， 特别是 IBD 相关疾病，并监督流式细胞术服务的运营。